Women's Health Advocate Amy Schumer Joins TMRW Life Sciences as Investor
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- TMRW Life Sciences, Inc. (TMRW), creator of the world's first and only automated, software-guided specimen management platform for frozen eggs and embryos used for in vitro fertilization (IVF), announced today that the award-winning actress, New York Times best-selling author, and IVF patient Amy Schumer is a new investor to TMRW.
- That's why I am proud to invest in TMRW.
- As an IVF mom, I know first-hand the comfort that increased levels of information and transparency bring," said Tara Comonte, CEO of TMRW.
- TMRW Life Sciences has created the only FDA-cleared automated solution that digitally tracks, monitors, and manages frozen eggs and embryos used in IVF.
- Founded in 2018, TMRW Life Sciences, Inc. is a life sciences technology company that provides safety and transparency to modernize and transform IVF.